The Philippines is introducing a new cancer treatment technology called the Oncothermia EHY-2030. This device uses modulated radiofrequency waves to target and damage cancer cells.
The Oncothermia EHY-2030 is designed to be more precise and comfortable than traditional hyperthermia treatments. It features an automatic tuning system, a user-friendly touchscreen interface, and a flexible electrode ring for better patient comfort.
The Oncothermia EHY-2030 is intended to be used alongside traditional cancer therapies like chemotherapy and radiation. It aims to improve the effectiveness of these treatments.
A product launch event for the Oncothermia EHY-2030 was held yesterday, June 1, 2024. Leading researchers and clinicians in oncology and hyperthermia were present to discuss the technology.
A new hope for cancer patients
Life1 Corporation and Oncotherm Group introduce Oncothermia EHY-2030, a medical treatment designed to enhance traditional tumor therapies to increase and improve patient survival time.
At a glance
The fight against cancer in the Philippines is taking a monumental step forward as Life1 Corporation, in collaboration with Oncotherm Group, is set to unveil the Oncothermia EHY-2030, a complementary device whose goal is to enhance the efficacy of traditional cancer therapies.
Cancer remains one of the leading causes of mortality in the Philippines. Despite advancements in medical technology, cancer treatment in the country faces numerous challenges, including limited access to advanced therapies, high treatment costs, and sometimes a significant burden on patients and their families. These stress points highlight the urgent need for innovative solutions that can improve patient outcomes and accessibility.
With new therapies offering hope and improved survival rates, it is evident cancer treatment is continuously evolving. Among these advancements, hyperthermia treatments have emerged as a promising approach. According to the National Cancer Institute, “hyperthermia” involves raising the temperature of cancer cells to damage and kill them, often used in conjunction with other therapies such as chemotherapy and radiation.
Oncothermia, a specialized form of hyperthermia, enhances the efficacy of cancer treatments by selectively targeting cancer cells using modulated radiofrequency (RF) waves, sparing healthy tissue and minimizing side effects.
The Oncothermia EHY-2030 and how it provides comfortable and innovative cancer treatment
Oncotherm Group's latest innovation, the Oncothermia EHY-2030 Model, represents a significant leap in cancer treatment technology. This state-of-the-art tool aims to harness the power of precise hyperthermia to complement traditional cancer therapies and enhance their efficacy.
It features an automatic controlled step-motor tuning system for rapid impedance matching, an advanced RF generator, and an electronically controlled smart electrode applicator for easy and accurate positioning. The user-friendly touchscreen interface allows comprehensive control of treatment and technical parameters. The flexible electrode ring ensures direct patient contact and comfort, while controlled surface temperature maintains patient comfort throughout the treatment. Additionally, the tool includes a hand-held emergency stop for immediate patient use and an integrated patient management system for complete registration and archiving of medical and technical data.
The introduction of Oncothermia EHY-2030 Model is a significant milestone in cancer care for the Philippines. This advanced tool offers a new dimension in cancer therapy, combining cutting-edge technology with patient-centric features.
Bringing the Oncothermia EHY-2030 Model to the Philippines
Life1 Corporation, a trading company based in the Philippines led by respected medical experts, in partnership with Oncotherm Group, an international provider of advanced cancer treatment technology, is set to introduce a new cancer treatment technology in the Philippines.
A product launch event was held yesterday, June 1, 2024, at the prestigious Fairmont Hotel in Makati, Philippines. It brought together leading researchers, clinicians, and pioneers in oncology, hyperthermia, and medical technology including Mr. Balázs Ács, CEO of Oncotherm Group; Prof. Dr. András Szász, Ph.D., Founder of Oncotherm; Prof. Dr. Pirus Ghadjar, M.D., Ph.D., Senior Physician and Head of Hyperthermia Department at Charité – Universitätsmedizin Berlin, Dr. Habil A. Marcell Szász, MD., Ph.D., Head of Science; Prof Dr. Magdolna Dank, MD., Ph.D., Director of Cancer Center Semmelweis University Budapest, Hungary; Dr. Paul Mulholland, MD., Consultant in Medical Oncology and Honorary Associate Professor; Prof Dr.Elisabeth Arrojo, MD., Ph.D., Radiation Oncologist; and Dr. Carrie A. Minaar, Ph.D., Oncologic Hyperthermia Specialist.
The discussions covered the principles of modulated electro-hyperthermia (mEHT), the use of radiofrequency hyperthermia to improve cancer therapy, advancements in modulated electro-hyperthermia, and clinical evidence establishing the efficacy of mEHT in medical oncology.
The Oncothermia EHY-2030 heralds a new era in cancer therapy in the Philippines. By integrating advanced technology with patient-focused care, this innovative tool has the potential to significantly improve cancer therapy outcomes. Life1 Corporation and Oncotherm Group are proud to lead this revolutionary change, offering new hope and possibilities for cancer patients across the nation.